Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

Share this content:
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.
A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.

Positive topline results from a pivotal phase 2 trial of tislelizumab (an antibody-based PD-1 inhibitor) that included patients with relapsed/refractory classical Hodgkin lymphoma (cHL) were recently released by BeiGene, in collaboration with Celgene.1

Tislelizumab was tested in a single-arm trial of 70 Chinese patients with relapsed/refractory cHL who had either failed or were ineligible for autologous stem cell transplantation. The overall response rate was 73%, with a 50% complete response, and the median duration of response had not been reached by study completion.

The antibody is also being examined as a treatment for “non-small cell lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma; as well as [in] two global phase 2 trials in patients with previously treated hepatocellular carcinoma or with R/R mature T-and NK-cell lymphomas, and an additional pivotal phase 2 trial in China in urothelial cancer.”

Though there are numerous checkpoint inhibitors already on the market, with many others also in developmental phases, BeiGene noted in a release that tislelizumab is different in that it has an Fc region engineered specifically to “minimize potentially negative interactions with other immune cells, based on preclinical data.”

The Fc region of an antibody has an intracellular domain that may mediate some signaling to a variety of other immune cells. The signaling of these other types of cells is what is responsible for various immune responses — such as release of inflammation mediators, B-cell activation, endocytosis, phagocytosis, and cytotoxic attack — that patients may experience as adverse effects.2

Despite a focus on a modified Fc region, phase 1 trials showed that the immune-related events associated with administration of tislelizumab were “consistent with previous reports of other PD-1 antibodies for the treatment of cHL.”

The data from this study will be combined with additional follow-up data and included in BeiGene's biologics license application with the China Drug Administration later this year. Final results will be presented at an upcoming medical conference.

References

  1. BeiGene announces preliminary topline results of pivotal trial in China for anti-PD-1 antibody Tislelizumab in Hodgkin's lymphoma [press release]. http://ir.beigene.com/phoenix.zhtml?c=254246&p=irol-newsArticle&ID=2359339. Published July 22, 2018. Accessed July 23, 2018.
  2. Lazar GA, Chirina AJ, Dang W, et al, inventors; Xencor Inc, assignee. Optimized Fc variants. US patent 7,317,091  B2. January 8, 2008.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs